Table 2 Predicted impact on renal function-based carboplatin dosing of a change from existing sampling times to the new BNMS guidelines
From: Estimation of renal function and its potential impact on carboplatin dosing in children with cancer
Existing sampling times (h) | New sampling times (h) | Number of centres | Percentage of children who have a >10% change in carboplatin dose |
|---|---|---|---|
1, 2, 3 and 4 | 2,3 and 4 | 1 | 23 (21% increase/2% decrease) |
1, 2 and 3 | 2,3 and 4 | 3 | 52 (47% increase/5% decrease) |
2 and 4 | 2,3 and 4 | 5 | No change |
2, 3 and 4 | 2,3 and 4 | 8 | No change |
1, 3 and 4 | 2,3 and 4 | 1 | 27 (25% increase/2% decrease) |
2 and 3 | 2,3 and 4 | 1 | 33 (23% increase/10% decrease) |
Others | — | 2 | — |
